MAbMods™ Anti-Mouse PD-1 [Clone 29F.1A12 (LALA-PG)]

mAbMods™ Anti-Mouse PD-1 [Clone 29F.1A12 (LALA-PG)]

Product No.: P458

- -
- -
Product No.P458
Clone
29F.1A12 (LALA PG)
Target
PD-1
Product Type
Recombinant Monoclonal Antibody for in vivo use
Isotype
Mouse IgG2a

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Expression Host
HEK-293 Cells
FC Effector Activity
Muted
Recommended Dilution Buffer
Immunogen
Recombinant PD-1-Ig fusion protein
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
Formulation
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Recombinant antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Research Area
Immuno-Oncology

References & Citations

1.) Ardolino, M. et al. (2018) J Clin Invest. 128(10):4654-4668. PubMed
2.) Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117.
3.) Honjo, T. et al. (1992) EMBO J. 11:3887.
4.) Wurster S. et al. (2020) The Journal of Infectious Diseases 222(6):1989–994 Journal Link
5.) Lo, R. et al. (2021) Cancer Cell 39(10):1375-1387.e6

Formats Available

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.